Evidence map›Paper›PMID 40133765›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Generalizability of tau and amyloid plasma biomarkers in Alzheimer's disease cohorts of diverse genetic ancestries.

Anthony J Griswold, Farid Rajabli, Tianjie Gu, Jamie Arvizu, Charles G Golightly, Patrice L Whitehead, Kara L Hamilton-Nelson, Larry D Adams, Jose J Sanchez, Pedro R Mena and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Ancestry-specific effects ofmedRxiv : the preprint server for health sciences · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Gaps in biomedical research in frontotemporal dementia: A call for diversity and disparities focused research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Anthony J GriswoldJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Farid RajabliJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Tianjie GuJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Jamie ArvizuJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Charles G GolightlyJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Patrice L WhiteheadJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Kara L Hamilton-NelsonJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Larry D AdamsJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Jose J SanchezJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Pedro R MenaJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Takiyah D StarksMaya Angelou Center for Health Equity, Wake Forest University, Winston-Salem, North Carolina, USA.
Maryenela Illanes-ManriqueNeurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru.
Concepcion SilvaDepartment of Internal Medicine, Universidad Central Del Caribe, Bayamón, Puerto Rico, USA.
William S BushDepartment of Population & Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA.
Michael L CuccaroJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Jeffery M VanceJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Mario R Cornejo-OlivasNeurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru.
Briseida E Feliciano-AstacioDepartment of Internal Medicine, Universidad Central Del Caribe, Bayamón, Puerto Rico, USA.
Goldie S ByrdMaya Angelou Center for Health Equity, Wake Forest University, Winston-Salem, North Carolina, USA.
Gary W BeechamJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.
Jonathan L HainesDepartment of Population & Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA.
Margaret A Pericak-VanceJohn P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.

Funding

Recruitment and Retention for Alzheimer's Disease Diversity Genetic Cohorts in the ADSP (READD-ADSP)U19AG074865 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GOLDIE S. BYRD, William S Bush · 2022 to 2026
$55.3M
The Origins of Alzheimer Disease in African AmericansR01AG072547 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Rufus Olusola Akinyemi, GOLDIE S. BYRD · 2022 to 2026
$26.1M
Characterizing the Genetic Risk for Alzheimer Disease in African and Admixed African-American AncestriesU01AG084545 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GOLDIE S. BYRD, ANTHONY JOHN GRISWOLD · 2024 to 2026
$14.9M
Genomic Characterization of Alzheimer Disease Risk in Admixed Populations with Native American and Southern European Genetic AncestryR01AG070864 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Margaret A. Pericak-Vance, FARID RAJABLI · 2021 to 2026
$12.1M
Replication and Extension of ADSP Discoveries in African-AmericansU01AG052410 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BEECHAM, GARY WAYNE, BYRD, GOLDIE S. · 2016 to 2020
$5.2M
Genetic basis of neuropsychiatric symptoms in Alzheimer's diseaseU01AG079850 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gary Wayne Beecham, Edward D Huey · 2023 to 2026
$3.0M
The Origins of Alzheimer Disease in Individuals of African AncestryR56AG072547 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BEECHAM, GARY WAYNE, BYRD, GOLDIE S. · 2021 to 2021
$3.0M
Neuroanatomical associations with the factor structure underlying neuropsychiatric symptoms in Alzheimer's diseaseR01AG062268 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HUEY, EDWARD D · 2018 to 2022
$2.5M
Genomic, Epigenomic, and Transcriptomic Mechanisms of Contributing to Alzheimer's Disease Risk in Diverse Ancestral PopulationsRF1AG070935 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BUSH, WILLIAM S, GRISWOLD, ANTHONY JOHN · 2021 to 2021
$2.3M
Using RDoC Negative and Positive Valence Paradigms to Investigate the Mechanisms of Neuropsychiatric Symptoms (NPS) in Alzheimer's Disease and Related DementiasR01MH120794 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HUEY, EDWARD D · 2019 to 2023
$2.1M
Genomic, Epigenomic, and Transcriptomic Mechanisms of Contributing to Alzheimer's Disease Risk in Diverse Ancestral PopulationsR01AG070935 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BUSH, WILLIAM S, GRISWOLD, ANTHONY JOHN · 2024 to 2025
$1.5M
National Institutes of Health, National Institute on Aging AG052410National Institutes of Health, National Institute on Aging AG070864National Institutes of Health, National Institute on Aging AG070935National Institutes of Health, National Institute on Aging AG072547National Institutes of Health, National Institute on Aging AG074865National Institutes of Health, National Institute on Aging AG084545NIA NIH HHS R01 AG062268NIA NIH HHS R01 AG070864NIA NIH HHS R01 AG070935NIA NIH HHS R01 AG072547NIA NIH HHS R56 AG072547NIA NIH HHS RF1 AG070935NIA NIH HHS U01 AG052410NIA NIH HHS U01 AG079850NIA NIH HHS U01 AG084545NIA NIH HHS U19 AG074865NIMH NIH HHS R01 MH120794
6 · The paper itself

Abstract

introductionPlasma phosphorylated threonine 181 of tau (pTau181) and amyloid beta (Aβ) are biomarkers for differential diagnosis and preclinical detection of Alzheimer disease (AD). Given differences in AD risk across diverse populations, the generalizability of existing biomarker data is not assured.

methodsIn 2086 individuals of diverse genetic ancestries (African American, Caribbean Hispanic, and Peruvian), we measured plasma pTau181 and Aβ42/Aβ40. Differences in biomarkers between cohorts and clinical diagnosis groups and the potential discriminative performance of the two biomarkers were assessed.

resultspTau181 and Aβ42/Aβ40 were consistent across cohorts. Higher levels of pTau181 were associated with AD, while Aβ42/Aβ40 had minimal differences. Correspondingly, pTau181 had a greater predictive value than Aβ42/Aβ40; however, the area under the curve differed between cohorts. DISCUSSION: pTau181 as a plasma biomarker for clinical AD is generalizable across genetic ancestries, but its predictive value may vary. Combining genomic and biomarker data from diverse individuals will increase understanding of genetic risk and refine clinical diagnoses. HIGHLIGHTS: This is a diverse ancestry study of plasma biomarkers for AD. Plasma biomarkers were assessed in African Americans, Caribbean Hispanics, and Peruvians. Biomarker levels were consistent across the diverse cohorts. Plasma phosphorylated tau was higher in AD in all cohorts. Plasma biomarker findings in diverse cohorts largely generalize with existing European studies.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesPeptide Fragmentstau ProteinsAgedAged, 80 and overBiomarkersBlack or African AmericanCohort StudiesFemaleHispanic or LatinoHumansMaleMiddle AgedPeruAmyloid beta-PeptidesBiomarkersMAPT protein, humanPeptide Fragmentstau ProteinsAlzheimer's diseaseamyloiddiverse ancestryplasma biomarkerstau

Identifiers

PMID40133765
PMCPMC11936763

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.